Compare Nuscale Power Corporation (SMR) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuscale Power Corporation vs Tango Therapeutics Inc. — how do they compare? Nuscale Power Corporation trades at $5.64 (market cap $2.39B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Tango Therapeutics Inc. is the larger of the two by market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuscale Power Corporation for 30 Days and Tango Therapeutics Inc. for 0 Days on average.
| SMR | TNGX | |
|---|---|---|
Market Cap | $2.39B | $3.74B |
Volume | 42,309,613 | 3,438,781 |
Sector | Industrials | Health |
52-Week High | $53.43 | $32.90 |
52-Week Low | $5.83 | $7.50 |
Typical Hold Time | 30 Days | 0 Days |
Enterprise Value | $1.32B | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NuScale Power (SMR) trades at $6.495, down 3.06% today, with bearish technical signals dominating despite some oversold RSI readings. The company shows severe financial strain with negative net income margins of -3,888.7% and operating cash flow deficits, though it maintains strong analyst support with a $11.25 consensus price target. Recent news highlights ongoing legal investigations and competitive pressures in the nuclear energy sector.
The stock faces significant fundamental challenges with massive losses and cash burn, but offers speculative upside if commercialization efforts succeed. Key risks include execution missteps, dilution concerns, and intense SMR competition. With 50% analyst buy ratings but bearish technicals, SMR represents a high-risk, high-reward opportunity in the emerging nuclear energy space.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
